Benefits
Fasting blood glucose and HbA1c reduction
Clinical trials in adults with type 2 diabetes show meaningful reductions in fasting glucose and HbA1c over 8-12 weeks of gynostemma supplementation. Effect sizes comparable to early-line metabolic interventions; complementary to standard care.
AMPK activation mechanism
Gypenosides activate AMP-activated protein kinase (AMPK) — the same metabolic pathway targeted by metformin and berberine. Mechanism explains the broad metabolic effects on glucose, lipids, and energy regulation.
Insulin sensitivity improvement
Trials show improved insulin sensitivity (HOMA-IR reduction) in adults with insulin resistance and metabolic syndrome. Combined with diet and exercise, gynostemma supplementation produces additive metabolic improvements.
Blood pressure reduction
Modest but consistent reductions in systolic and diastolic blood pressure in adults with mild hypertension. Effects are smaller than first-line antihypertensives but useful as adjunct support.
Lipid profile improvement
Clinical trials show reductions in total cholesterol, LDL, and triglycerides with gynostemma supplementation over weeks of use. Cardiovascular benefit beyond pure glycemic effects.
Exercise capacity and stamina
Some trials in healthy adults show improvements in exercise tolerance and reduced perceived exertion. Effects are modest and most pronounced in untrained or older populations.
Adaptogenic stress modulation
Traditional use and emerging trials support gynostemma as an adaptogen — modulating stress response and supporting general resilience. Less validated than ashwagandha or rhodiola for this use case.
Mechanism of action
AMPK Thr172 phosphorylation activation
AMP-activated protein kinase activation via Thr172 phosphorylation — same target as metformin and exercise. Central energy-sensor activation drives downstream metabolic effects.
Hypolipidemic SREBP / HMGCR / PCSK9 pathways
Cholesterol regulation via SREBP, HMGCR, and PCSK9 pathways. Triglyceride regulation via PPAR / UCP-1 / PGC-1α / PRDM16 and (SREBP-1c)-ACC/FAS-CPT1. Multi-pathway lipid metabolism modulation.
Insulin sensitivity + glucose uptake
Insulin sensitivity improvement and glucose uptake enhancement — trial data demonstrated ~2% HbA1c reduction in drug-naïve T2D.
Mitochondrial respiration + oxygen flux
Increased muscle oxygen flux. Mitochondrial respiration enhancement contributes to the exercise performance and endurance effects.
Leptin reduction + adipose modulation
Leptin reduction and broader adipose tissue modulation contribute to body composition improvements.
Anxiolytic via HPA axis
Anxiolytic effects via HPA axis modulation. Adaptogen mechanism for the chronic stress and anxiety indication.
Clinical trials
Clinical evidence on Gynostemma pentaphyllum (Jiaogulan / Southern Ginseng) for the indications and outcomes described.
Clinical population described in trial publication.
NCT01254084. Hanoi Medical University + Karolinska Institutet phase 1/2 clinical trial in 24 drug-naïve T2D patients. 6 g/day GP tea (3 g BID, 30 min before meals) × 10-12 weeks. Plasma glucose reduction with ~2% HbA1c decrease. Pivotal T2D evidence.
16-pt 4-week crossover with 450 mg dried leaf extract (= 2.25 g dry leaf).
Clinical population described in trial publication.
16-pt 4-week crossover with 450 mg dried leaf extract (= 2.25 g dry leaf). Lower leptin and blood glucose, improved 20-km time trial, higher muscle oxygen flux, increased muscle AMPK Thr172 phosphorylation post-exercise. Mechanism + performance integration.
Clinical evidence on Gynostemma pentaphyllum (Jiaogulan / Southern Ginseng) for the indications and outcomes described.
Clinical population described in trial publication.
Rao A et al. 2022 (J Hum Nutr Diet, doi:10.1111/jhn.12936). ActivAMP® 80-pt 12-week obesity clinical trial. Total abdominal fat, body weight, body fat mass, %body fat, and BMI all significantly decreased. Multi-domain body composition evidence at scale.